C-Reactive Protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Tenforde, Mark W ^a   Gupte, Nikhil ^a   Dowdy, David W ^b   Asmuth, David M ^c   Balagopal, Ashwin ^a   Pollard, Richard B ^c   Sugandhavesa, Patcharaphan ^d   Lama, Javier R ^e   Pillay, Sandy ^f   Cardoso, Sandra W ^g   Pawar, Jyoti ^h   Santos, Breno ⁱ   Riviere, Cynthia ^j   Mwelase, Noluthando ^k   Kanyama, Cecilia ^l   Kumwenda, Johnstone ^a   Hakim, James G ^m   Kumarasamy, Nagalingeswaran ⁿ   Bollinger, Robert ^a   Semba, Richard D ^a   Campbell, Thomas B ^o   Gupta, Amita ^a,b   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHIANG MAI UNIVERSITY   (Thailand)

^e ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g Funda??o Oswaldo Cruz   (Brazil)

^h NATIONAL AIDS RESEARCH INSTITUTE   (India)

ⁱ HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^j Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^k UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^l UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^m UNIVERSITY OF ZIMBABWE   (Zimbabwe)

ⁿ YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^o UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIRETROVIRUS AGENT; ATAZANAVIR; C REACTIVE PROTEIN; CD14 ANTIGEN; CD38 ANTIGEN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENDOTOXIN ANTIBODY; FERRITIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; IMMUNOGLOBULIN M; INTERLEUKIN 6; LAMIVUDINE PLUS ZIDOVUDINE; LIPOPOLYSACCHARIDE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA; CXCL10 PROTEIN, HUMAN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BODY MASS; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DOSAGE SCHEDULE COMPARISON; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOALBUMINEMIA; IMMUNOSTIMULATION; INCIDENCE; INCIDENTAL FINDING; INFLAMMATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS; UPREGULATION; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BLOOD; DEVELOPING COUNTRY; METABOLISM; RISK;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; C-REACTIVE PROTEIN; CHEMOKINE CXCL10; DEVELOPING COUNTRIES; FEMALE; HUMANS; INCIDENCE; LIPOPOLYSACCHARIDES; MALE; RISK; TUBERCULOSIS;

EID: 84923869697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117424     Document Type: Article

References (48)

1. Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, et al. (2011) Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): A systematic review and meta-analysis. PLoS One 6: e28691. doi: 10.1371/journal.pone.0028691 PMID: 22220193
2. Choun K, Thai S, Pe R, Lorent N, Lynen L, et al. (2013) Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in cambodia. Trans R Soc Trop Med Hyg 107: 235-242. doi: 10.1093/trstmh/trt001 PMID: 23324313
3. Sudfeld CR, Isanaka S, Aboud S, Mugusi FM, Wang M, et al. (2013) Association of serum albumin concentration with mortality, morbidity, CD4 T-cell reconstitution among tanzanians initiating antiretroviral therapy. J Infect Dis 207: 1370-1378. doi: 10.1093/infdis/jit027 PMID: 23319741
4. Kassa A, Teka A, Shewaamare A, Jerene D (2012) Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in addis ababa, ethiopia. Trans R Soc Trop Med Hyg 106: 363-370. doi: 10.1016/j.trstmh.2012.03.002 PMID: 22521216
5. Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades-Rodriguez M, et al. (2011) Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 subsaharan african HIV programs. J Acquir Immune Defic Syndr 57: 311-318. doi: 10.1097/QAI. 0b013e318218a713 PMID: 21423023
6. Worodria W, Massinga-Loembe M, Mayanja-Kizza H, Namaganda J, Kambugu A, et al. (2011) Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clin Dev Immunol 2011: 758350. doi: 10.1155/2011/758350 PMID: 21197091
7. Van Rie A, Westreich D, Sanne I (2011) Tuberculosis in patients receiving antiretroviral treatment: Incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 56: 349-355. doi: 10. 1097/QAI.0b013e3181f9fb39 PMID: 20926954
8. Dembele M, Saleri N, Carvalho AC, Saouadogo T, Hien AD, et al. (2010) Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in burkina faso. Int J Tuberc Lung Dis 14: 318-323. PMID: 20132623
9. Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA), ART Cohort Collaboration, Brinkhof MW, Egger M, Boulle A, et al. (2007) Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 45: 1518-1521. PMID: 17990236
10. Lawn SD, Badri M, Wood R (2005) Tuberculosis among HIV-infected patients receiving HAART: Long term incidence and risk factors in a south african cohort. AIDS 19: 2109-2116. PMID: 16284460
11. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, et al. (2011) Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: A systematic review and meta-analysis. J Acquir Immune Defic Syndr 56: 230-238. doi: 10.1097/QAI.0b013e31820b07ab PMID: 21239993
12. Welsh KJ, Abbott AN, Hwang SA, Indrigo J, Armitige LY, et al. (2008) A role for tumour necrosis factoralpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,60 -dimycolate induced granulomatous response. Microbiology 154: 1813-1824. doi: 10. 1099/mic.0.2008/016923-0 PMID: 18524936
13. Mihret A, Bekele Y, Bobosha K, Kidd M, Aseffa A, et al. (2013) Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J Infect 66: 357-365. doi: 10. 1016/j.jinf.2012.11.005 PMID: 23178506
14. Borgstrom E, Andersen P, Atterfelt F, Julander I, Kallenius G, et al. (2012) Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker. PLoS One 7: e43438. doi: 10.1371/journal.pone.0043438 PMID: 23144772
15. Yu Y, Zhang Y, Hu S, Jin D, Chen X, et al. (2012) Different patterns of cytokines and chemokines combined with IFN-gamma production reflect mycobacterium tuberculosis infection and disease. PLoS One 7: e44944. doi: 10.1371/journal.pone.0044944 PMID: 23028695
16. Hong JY, Jung GS, Kim H, Kim YM, Lee HJ, et al. (2012) Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis 16: e855-9. doi: 10.1016/j.ijid.2012.07.013 PMID: 22959355
17. Wang X, Jiang J, Cao Z, Yang B, Zhang J, et al. (2012) Diagnostic performance of multiplex cytokine and chemokine assay for tuberculosis. Tuberculosis (Edinb) 92: 513-520. doi: 10.1016/j.tube.2012.06. 005 PMID: 22824465
18. Chegou NN, Essone PN, Loxton AG, Stanley K, Black GF, et al. (2012) Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. PLoS One 7: e38501. doi: 10.1371/journal.pone.0038501 PMID: 22693640
19. Kellar KL, Gehrke J, Weis SE, Mahmutovic-Mayhew A, Davila B, et al. (2011) Multiple cytokines are released when blood from patients with tuberculosis is stimulated with mycobacterium tuberculosis antigens. PLoS One 6: e26545. doi: 10.1371/journal.pone.0026545 PMID: 22132075
20. Pokkali S, Das SD (2009) Augmented chemokine levels and chemokine receptor expression on immune cells during pulmonary tuberculosis. Hum Immunol 70: 110-115. doi: 10.1016/j.humimm.2008. 11.003 PMID: 19100801
21. Aabye MG, Ruhwald M, Praygod G, Jeremiah K, Faurholt-Jepsen M, et al. (2010) Potential of interferon-gamma-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur Respir J 36: 1488-1490. doi: 10.1183/09031936.00039010 PMID: 21119209
22. Goletti D, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, et al. (2010) Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS One 5: e12577. doi: 10.1371/journal.pone.0012577 PMID: 20830287
23. Kabeer BS, Sikhamani R, Raja A (2010) Comparison of interferon gamma and interferon gammainducible protein-10 secretion in HIV-tuberculosis patients. AIDS 24: 323-325. doi: 10.1097/QAD. 0b013e328334895e PMID: 20010069
24. Nowroozalizadeh S, Mansson F, da Silva Z, Repits J, Dabo B, et al. (2010) Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis 201: 1150-1154. doi: 10.1086/ 651430 PMID: 20199244
25. Merlini E, Bai F, Bellistri GM, Tincati C, d'Arminio Monforte A, et al. (2011) Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 6: e18580. doi: 10.1371/journal.pone.0018580 PMID: 21494598
26. Marchetti G, Bellistri GM, Borghi E, Tincati C, Ferramosca S, et al. (2008) Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22: 2035-2038. doi: 10.1097/QAD.0b013e3283112d29 PMID: 18784466
27. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780-790. doi: 10.1093/infdis/jiq118 PMID: 21252259
28. Cao W, Jamieson BD, Hultin LE, Hultin PM, Detels R (2009) Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res Hum Retroviruses 25: 183-191. doi: 10.1089/aid.2008.0140 PMID: 19239357
29. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, et al. (2011) Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 203: 1637-1646. doi: 10.1093/infdis/jir134 PMID: 21592994
30. Lawn SD, Kerkhoff AD, Vogt M, Wood R (2013) Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. Int J Tuberc Lung Dis 17: 636-643. doi: 10.5588/ ijtld.12.0811 PMID: 23575330
31. McDermid JM, Hennig BJ, van der Sande M, Hill AV, Whittle HC, et al. (2013) Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: An 11-year retrospective cohort study. BMC Infect Dis 13: 48-2334-13-48. doi: 10.1186/1471-2334-13-48 PMID: 23360117
32. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, et al. (2010) Inflammation and mortality in HIVinfected adults: Analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 55: 316-322. doi: 10. 1097/QAI.0b013e3181e66216 PMID: 20581689
33. Drain PK, Kupka R, Msamanga GI, Urassa W, Mugusi F, et al. (2007) C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS 21: 2067-2075. PMID: 17885297
34. Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, et al. (2006) C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 166: 64-70. PMID: 16401812
35. Isanaka S, Aboud S, Mugusi F, Bosch RJ, Willett WC, et al. (2012) Iron status predicts treatment failure and mortality in tuberculosis patients: A prospective cohort study from dar es salaam, tanzania. PLoS One 7: e37350. doi: 10.1371/journal.pone.0037350 PMID: 22606361
36. McDermid JM, van der Loeff MF, Jaye A, Hennig BJ, Bates C, et al. (2009) Mortality in HIV infection is independently predicted by host iron status and SLC11A1 and HP genotypes, with new evidence of a gene-nutrient interaction. Am J Clin Nutr 90: 225-233. doi: 10.3945/ajcn.2009.27709 PMID: 19474129
37. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, et al. (2012) Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: A randomized clinical trial in diverse multinational settings. PLoS Med 9: e1001290. PMID: 22936892
38. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516-523. doi: 10.1016/S1473-3099(08)70184-1 PMID: 18652998
39. Balagopal A, Gama L, Franco V, Russell JN, Quinn J, et al. (2012) Detection of microbial translocation in HIV and SIV infection using the limulus amebocyte lysate assay is masked by serum and plasma. PLoS One 7: e41258. PMID: 22870212
40. World Health Organization (2011) Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System.
41. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, et al. (2011) Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the united states and canada: Implications for tuberculosis screening. J Infect Dis 204: 893-901. doi: 10.1093/infdis/jir421 PMID: 21849286
42. Bhowmik A, Bhandari S, De R, Guha SK (2012) Predictors of mortality among HIV-infected patients initiating anti retroviral therapy at a tertiary care hospital in eastern india. Asian Pac J Trop Med 5: 986-990. doi: 10.1016/S1995-7645(12)60187-4 PMID: 23199719
43. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, et al. (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168: 3195-3204. PMID: 11907072
44. Ferrero E, Biswas P, Vettoretto K, Ferrarini M, Uguccioni M, et al. (2003) Macrophages exposed to mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: Focus on gammadelta cells. Immunology 108: 365-374. PMID: 12603603
45. Jiao Y, Zhang T, Wang R, Zhang H, Huang X, et al. (2012) Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. Viral Immunol 25: 333-337. doi: 10.1089/vim.2012.0011 PMID: 22788418
46. Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, et al. (2008) IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 13: 969-976. PMID: 19195322
47. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, et al. (2012) Antiretroviral therapy for prevention of tuberculosis in adults with HIV: A systematic review and meta-analysis. PLoS Med 9: e1001270. doi: 10.1371/journal.pmed.1001270 PMID: 22911011
48. Pai M (2010) Spectum of latent tuberculosis-existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol 8: 242. doi: 10.1038/nrmicro2236-c1 PMID: 20084059